✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Lexaptepid Pegol is an investigational drug.
There have been 4 clinical trials for Lexaptepid Pegol. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2012.
The most common disease conditions in clinical trials are Anemia, Chronic Disease, and Kidney Failure, Chronic. The leading clinical trial sponsors are NOXXON Pharma AG and [disabled in preview].
Recent Clinical Trials for Lexaptepid Pegol
|Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients||NOXXON Pharma AG||Phase 1/Phase 2|
|Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer||NOXXON Pharma AG||Phase 2|
|Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model||NOXXON Pharma AG||Phase 1|